The DSMB meets periodically to review the safety results to date (Merck is blind to these data) to be certain that patients on Vytorin are not experiencing any unexpected safety issues.

FORBES: Cholesterol Drug Heart Study Continues, But Will Merck's Vytorin Really IMPROVE-IT?